Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14
pubmed:dateCreated
2002-6-26
pubmed:abstractText
Intravenous infusion of bone marrow stromal cells (BMSCs) has been proposed as a means to support hematopoiesis in bone marrow transplantation or as a vehicle for gene therapy. However, it seems that this route of injection leads to engraftment of a small proportion of BMSCs, possibly because they are unable to cross the endothelial barrier. We have transplanted human BMSCs, ex vivo expanded and transduced with a retrovirus encoding the human erythropoietin gene, either intravenously or subcutaneously with or without a tridimensional scaffold in non-conditioned NOD/SCID mice. Efficiency of engraftment was evaluated monitoring the hematocrit levels. Systemic infusion never significantly increased hematocrit levels, whereas subcutaneous transplantation of the same number of cells induced an important increase of the hematocrit (approximately 70%) for at least 2 months. A substantial increase in the length of the response was observed when cells were subcutaneously transplanted in a tridimensional scaffold. To determine whether the transient effect was due to cell loss or to reduction in expression, the cells implanted into a tridimensional scaffold were recovered, expanded in vitro, and re-implanted in a new group of mice. Again the hematocrit levels rose 2 weeks after transplantation ( approximately 70%). These results demonstrate that ex vivo expanded human BMSCs are not quantitatively transplantable by systemic infusion in non-conditioned recipients, whereas the local implantation into a tridimensional scaffold allows long-term engraftment and efficient expression of a foreign gene.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0969-7128
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
915-21
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12085239-Adipocytes, pubmed-meshheading:12085239-Animals, pubmed-meshheading:12085239-Bone Marrow Transplantation, pubmed-meshheading:12085239-Bone and Bones, pubmed-meshheading:12085239-Cell Differentiation, pubmed-meshheading:12085239-Chondrocytes, pubmed-meshheading:12085239-Erythropoietin, pubmed-meshheading:12085239-Female, pubmed-meshheading:12085239-Gene Therapy, pubmed-meshheading:12085239-Genetic Vectors, pubmed-meshheading:12085239-Infusions, Intravenous, pubmed-meshheading:12085239-Injections, Subcutaneous, pubmed-meshheading:12085239-Mice, pubmed-meshheading:12085239-Mice, SCID, pubmed-meshheading:12085239-Retroviridae, pubmed-meshheading:12085239-Stromal Cells, pubmed-meshheading:12085239-Transduction, Genetic, pubmed-meshheading:12085239-Transplantation, Homologous
pubmed:year
2002
pubmed:articleTitle
Enhanced engraftment of EPO-transduced human bone marrow stromal cells transplanted in a 3D matrix in non-conditioned NOD/SCID mice.
pubmed:affiliation
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't